Biotech firm Amarantus Bioscience has appointed Iain Ross to its board of directors.
Ross is currently chairman of Ark Therapeutics and Biomer Technology. He is also a non-executive director of expressed RNAi firm Benitec Biopharma, and previously served as chairman of Silence Therapeutics.
Voyager Therapeutics has named Steven Paul, its interim president of research and development, as its new CEO.
Paul replaces Third Rock Venture partner Mark Levin, who served as the startup's interim CEO following the venture capital company's investment in Voyager earlier this year. Levin has now become Voyager's chairman.